Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short chemo-radioimmunotherapy with Zevalin for relapsed follicular lymphoma
ISRCTN44808098Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan and rituximab in follicular lymphoma (FL), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Overall response rate. Started Apr 2008; status: completed.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ISRCTN44808098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44808098.